New immune cell therapy takes on virus after transplant
NCT ID NCT07368634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment for Epstein-Barr virus (EBV) that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and destroy virus-infected cells. Up to 18 adult patients who have persistent EBV despite standard care will receive up to three infusions. The main goal is to check safety, but researchers will also see if the virus clears from the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EBV-TCR-T cells (engineered immune cells designed to target and kill Epstein-Barr virus-infected cells)
What this could lead to
If successful, this could offer a new treatment option for controlling Epstein-Barr virus after stem cell transplants, potentially preventing serious complications like lymphoproliferative disorders.
What could go wrong
This is a very early, small trial (18 participants) testing safety first. The treatment may not work, and there are risks like cytokine release syndrome or other infusion reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••